Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Correlation Study Between SMA Blood Flow Reactivity and Acute Gastrointestinal Injury in Critically Ill Patients

NCT07001943 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2025-06-01
Last updated
2025-09-05

Condition(s) studied

Intestinal IschemiaCritical IllnessEnteral Nutrition FeedingHemodynamicsUltrasonography, Doppler

Investigational drug(s) / intervention(s)

enteral nutrition

enteral nutrition: We'll use an enteral nutrition intervention with intact protein formulations. Initiate nasogastric tube feeding at 20ml/h and continue for 24 hours. Adjust feeding strategies based on patients' SMA blood flow reactivity.

Study summary

This study aims to address the challenges of enteral nutrition support in critically ill ICU patients with varying gastrointestinal function. We'll use bedside Doppler ultrasound to monitor superior mesenteric artery (SMA) blood flow changes post - feeding, exploring its correlation with Acute Gastrointestinal Injury (AGI) and other hemodynamic indicators. Our goals are to identify the patterns of SMA blood flow changes, establish a predictive model linking SMA blood flow reactivity to AGI risk, and propose individualized enteral nutrition strategies based on intestinal hemodynamics. Through this innovative approach, we hope to enhance the safety of enteral nutrition, reduce AGI incidence, and improve patient outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged ≥18 years and ≤80 years. * Admitted to the study with a expected stay of more than 72 hours. * Require initiation of enteral nutrition support. Exclusion Criteria: * Pre-existing severe gastrointestinal diseases. * Patients with gastrointestinal bleeding. * Patients with bowel obstruction. * Pregnant or lactating women. * Patients with contraindications to bedside Doppler ultrasound.

Primary outcome measure(s)

  • feeding intolerance — From enrollment to the end of treatment at 3 days
    the incidence of feeding intolerance, defined as the frequency of feeding interruptions or reductions due to gastrointestinal complications like vomiting, gastric residuals, or abdominal distension during the study period.

Trial sites (1)

FacilityCityRegionStatus
Peking union medical college hospital Beijing Beijing Municipality Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07001943 on ClinicalTrials.gov ↗ ← All trials in China